Published in Am J Pathol on April 01, 1996
Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol (1998) 2.85
Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther (2011) 2.51
Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss. Am J Pathol (2000) 1.66
The genetics and neuropathology of Alzheimer's disease. Acta Neuropathol (2012) 1.56
Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities. Proc Natl Acad Sci U S A (1996) 1.52
Amyloid angiopathy and variability in amyloid beta deposition is determined by mutation position in presenilin-1-linked Alzheimer's disease. Am J Pathol (2001) 1.34
Cerebrovascular dysfunction in amyloid precursor protein transgenic mice: contribution of soluble and insoluble amyloid-beta peptide, partial restoration via gamma-secretase inhibition. J Neurosci (2008) 1.27
Correlating familial Alzheimer's disease gene mutations with clinical phenotype. Biomark Med (2010) 1.21
Dense-core senile plaques in the Flemish variant of Alzheimer's disease are vasocentric. Am J Pathol (2002) 1.11
Possible mechanisms of action of NSAIDs and related compounds that modulate gamma-secretase cleavage. Curr Top Med Chem (2008) 0.99
The relationship between cerebral amyloid angiopathy and cortical microinfarcts in brain ageing and Alzheimer's disease. Neuropathol Appl Neurobiol (2013) 0.98
Comparison of Abeta levels in the brain of familial and sporadic Alzheimer's disease. Neurochem Int (2009) 0.96
Insights into Alzheimer disease pathogenesis from studies in transgenic animal models. Clinics (Sao Paulo) (2011) 0.96
Contribution of reactive oxygen species to cerebral amyloid angiopathy, vasomotor dysfunction, and microhemorrhage in aged Tg2576 mice. Proc Natl Acad Sci U S A (2015) 0.92
Molecular plasticity regulates oligomerization and cytotoxicity of the multipeptide-length amyloid-β peptide pool. J Biol Chem (2012) 0.90
Bivalent ligand containing curcumin and cholesterol as fluorescence probe for Aβ plaques in Alzheimer's disease. ACS Chem Neurosci (2011) 0.89
Resorufin analogs preferentially bind cerebrovascular amyloid: potential use as imaging ligands for cerebral amyloid angiopathy. Mol Neurodegener (2011) 0.89
Neuropathologic assessment of participants in two multi-center longitudinal observational studies: the Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN). Neuropathology (2015) 0.88
Liposomes for Targeted Delivery of Active Agents against Neurodegenerative Diseases (Alzheimer's Disease and Parkinson's Disease). J Drug Deliv (2011) 0.88
RGS2 expression predicts amyloid-β sensitivity, MCI and Alzheimer's disease: genome-wide transcriptomic profiling and bioinformatics data mining. Transl Psychiatry (2016) 0.75
Phenotypic Similarities Between Late-Onset Autosomal Dominant and Sporadic Alzheimer Disease: A Single-Family Case-Control Study. JAMA Neurol (2016) 0.75
Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun (1984) 20.07
Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A (1985) 16.10
Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature (1995) 9.39
The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry (1993) 7.26
Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature (1992) 7.16
Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature (1992) 6.51
Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron (1994) 6.41
Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science (1992) 5.22
An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science (1994) 5.10
Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science (1990) 4.71
Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. Science (1993) 3.95
Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem (1993) 3.52
Amyloid beta protein (A beta) deposition: A beta 42(43) precedes A beta 40 in Down syndrome. Ann Neurol (1995) 3.34
Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J Biol Chem (1995) 3.17
Normal and abnormal biology of the beta-amyloid precursor protein. Annu Rev Neurosci (1994) 2.81
beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc Natl Acad Sci U S A (1993) 2.80
Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene. Nat Genet (1992) 2.40
Differences between vascular and plaque core amyloid in Alzheimer's disease. J Neurochem (1988) 2.24
Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci U S A (1994) 1.91
Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch Biochem Biophys (1993) 1.90
Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide. Nature (1993) 1.85
Characterization of beta-amyloid peptide from human cerebrospinal fluid. J Neurochem (1993) 1.71
Protein chemical and immunocytochemical studies of meningovascular beta-amyloid protein in Alzheimer's disease and normal aging. Brain Res (1988) 1.59
Chemical characterization of A beta 17-42 peptide, a component of diffuse amyloid deposits of Alzheimer disease. J Biol Chem (1994) 1.56
Hereditary cerebral hemorrhage with amyloidosis in patients of Dutch origin is related to Alzheimer disease. Proc Natl Acad Sci U S A (1987) 1.56
Mis-sense mutation Val----Ile in exon 17 of amyloid precursor protein gene in Japanese familial Alzheimer's disease. Lancet (1991) 1.39
Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid. Biochem Biophys Res Commun (1994) 1.27
Polyclonals to beta-amyloid(1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum. Brain Res (1994) 1.22
Clinical comparison of Alzheimer's disease in pedigrees with the codon 717 Val-->Ile mutation in the amyloid precursor protein gene. Neurobiol Aging (1994) 1.18
APP717 missense mutation affects the ratio of amyloid beta protein species (A beta 1-42/43 and a beta 1-40) in familial Alzheimer's disease brain. J Biol Chem (1994) 1.18
Altered cleavage and secretion of a recombinant beta-APP bearing the Swedish familial Alzheimer's disease mutation. Nat Genet (1994) 1.12
Amyloid beta protein deposition in normal aging has the same characteristics as that in Alzheimer's disease. Predominance of A beta 42(43) and association of A beta 40 with cored plaques. Am J Pathol (1996) 1.07
Familial Alzheimer's disease with the amyloid precursor protein position 717 mutation and sporadic Alzheimer's disease have the same cytoskeletal pathology. Neurosci Lett (1992) 0.99
Amyloid precursor protein mutation causes Alzheimer's disease in a Swedish family. Neurosci Lett (1994) 0.95
Increased beta-amyloid release and levels of amyloid precursor protein (APP) in fibroblast cell lines from family members with the Swedish Alzheimer's disease APP670/671 mutation. FEBS Lett (1994) 0.91
Development of a monoclonal antibody specific for the COOH-terminal of beta-amyloid 1-42 and its immunohistochemical reactivity in Alzheimer's disease and related disorders. Am J Pathol (1994) 0.91
Hereditary cerebral hemorrhage with amyloidosis (Dutch): a model for congophilic plaque formation without neurofibrillary pathology. Acta Neuropathol (1994) 0.89
Microglial cells and amyloid beta protein (A beta) deposition; association with A beta 40-containing plaques. Acta Neuropathol (1995) 0.87
Lewy bodies in the brain of two members of a family with the 717 (Val to Ile) mutation of the amyloid precursor protein gene. Neurosci Lett (1994) 0.87
Beta A4 protein deposition in familial Alzheimer's disease with the mutation in codon 717 of the beta A4 amyloid precursor protein gene and sporadic Alzheimer's disease. Neurosci Lett (1993) 0.84
Pathological changes in the brain of a patient with familial Alzheimer's disease having a missense mutation at codon 717 in the amyloid precursor protein gene. Neurosci Lett (1992) 0.84
Spectrum of amyloid beta-protein immunoreactivity in hereditary Alzheimer disease with a guanine to thymine missense change at position 1924 of the APP gene. Brain Res (1992) 0.84
Tau pathology in a case of familial Alzheimer's disease with a valine to glycine mutation at position 717 in the amyloid precursor protein. Neurosci Lett (1992) 0.80
Screening of the mis-sense mutation producing the 717Val-->Ile substitution in the amyloid precursor protein in Japanese familial and sporadic Alzheimer's disease. J Neurol Sci (1993) 0.77
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
Current concepts in mild cognitive impairment. Arch Neurol (2001) 18.09
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 15.24
Influence of social network on occurrence of dementia: a community-based longitudinal study. Lancet (2000) 7.31
Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron (1994) 6.41
Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol (1998) 5.47
Alzheimer's disease: insolubility of partially purified paired helical filaments in sodium dodecyl sulfate and urea. Science (1982) 5.42
The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci (2001) 5.29
Ubiquitin is a component of paired helical filaments in Alzheimer's disease. Science (1987) 5.06
Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci (1999) 5.01
Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. Brain (1996) 4.61
A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet (1992) 4.31
Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images. Lancet (2001) 4.28
Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology (1994) 4.24
Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron (1992) 4.22
A variety of cerebral amyloid deposits in the brains of the Alzheimer-type dementia demonstrated by beta protein immunostaining. Acta Neuropathol (1988) 4.10
Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet (1999) 4.02
Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci (1989) 4.01
Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Arch Neurol (2000) 3.99
Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci U S A (1993) 3.73
Antibodies to paired helical filaments in Alzheimer's disease do not recognize normal brain proteins. Nature (1983) 3.67
Prion dementia without characteristic pathology. Lancet (1990) 3.66
Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol (1999) 3.62
Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology (2005) 3.58
Loss of function of a rice brassinosteroid insensitive1 homolog prevents internode elongation and bending of the lamina joint. Plant Cell (2000) 3.56
Extrapyramidal signs in dementia of Alzheimer type. Lancet (1989) 3.52
Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology (2009) 3.49
Patterns of temporal lobe atrophy in semantic dementia and Alzheimer's disease. Ann Neurol (2001) 3.43
Amyloid beta protein (A beta) deposition: A beta 42(43) precedes A beta 40 in Down syndrome. Ann Neurol (1995) 3.34
Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett (1998) 3.26
Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol (2001) 3.19
Unaltered susceptibility to BSE in transgenic mice expressing human prion protein. Nature (1996) 3.09
Correlation between rates of brain atrophy and cognitive decline in AD. Neurology (1999) 3.07
Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol (2002) 3.02
The prevalence and causes of dementia in people under the age of 65 years. J Neurol Neurosurg Psychiatry (2003) 2.97
Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron (1995) 2.90
Visualisation and quantification of rates of atrophy in Alzheimer's disease. Lancet (1996) 2.89
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
The genetic causes of basal ganglia calcification, dementia, and bone cysts: DAP12 and TREM2. Neurology (2005) 2.77
GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer's disease. Nat Med (1995) 2.77
Predictors of progression from mild cognitive impairment to Alzheimer disease. Neurology (2007) 2.72
Neuronal loss in the frontal cortex in HIV infection. Lancet (1991) 2.71
HIV-infected subjects with the E4 allele for APOE have excess dementia and peripheral neuropathy. Nat Med (1998) 2.68
Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol (1996) 2.68
Heritability for Alzheimer's disease: the study of dementia in Swedish twins. J Gerontol A Biol Sci Med Sci (1997) 2.59
Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study. Acta Neuropathol (1988) 2.59
Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer's disease. J Biochem (1986) 2.54
Species-barrier-independent prion replication in apparently resistant species. Proc Natl Acad Sci U S A (2000) 2.50
Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology (2000) 2.47
Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol (1998) 2.47
Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol (2007) 2.47
The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway. Nat Med (1995) 2.44
The course of cognitive impairment in preclinical Alzheimer disease: three- and 6-year follow-up of a population-based sample. Arch Neurol (2000) 2.37
One of the antigenic determinants of paired helical filaments is related to tau protein. J Biochem (1986) 2.37
Association between schizophrenia and homozygosity at the dopamine D3 receptor gene. J Med Genet (1992) 2.32
The carboxyl third of tau is tightly bound to paired helical filaments. Neuron (1988) 2.31
The appropriateness of drug use in an older nondemented and demented population. J Am Geriatr Soc (2001) 2.30
Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci U S A (1999) 2.29
Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. J Biol Chem (2000) 2.27
Education and dementia: what lies behind the association? Neurology (2007) 2.26
Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan. Ann Neurol (1998) 2.25
Expression of multiple tau isoforms and microtubule bundle formation in fibroblasts transfected with a single tau cDNA. J Cell Biol (1989) 2.24
Low blood pressure and dementia in elderly people: the Kungsholmen project. BMJ (1996) 2.20
Inorganic polyphosphate and the induction of rpoS expression. Proc Natl Acad Sci U S A (1997) 2.19
Frontotemporal lobar degeneration and ubiquitin immunohistochemistry. Neuropathol Appl Neurobiol (2004) 2.19
Alzheimer's A beta(1-42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells. Nat Med (1997) 2.15
Very old women at highest risk of dementia and Alzheimer's disease: incidence data from the Kungsholmen Project, Stockholm. Neurology (1997) 2.14
Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology (2004) 2.10
Rates of global and regional cerebral atrophy in AD and frontotemporal dementia. Neurology (2001) 2.09
Proline-directed and non-proline-directed phosphorylation of PHF-tau. J Biol Chem (1995) 2.09
Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol (1999) 2.08
An estimate of the worldwide prevalence and direct costs of dementia in 2003. Dement Geriatr Cogn Disord (2006) 2.08
The growth inhibitory factor that is deficient in the Alzheimer's disease brain is a 68 amino acid metallothionein-like protein. Neuron (1991) 2.05
Prevalence of Alzheimer's disease and other dementias in an elderly urban population: relationship with age, sex, and education. Neurology (1991) 2.05
Simultaneous liquid chromatographic determination of seventeen of the major monoamine neurotransmitters, precursors and metabolites. II. Assessment of human brain and cerebrospinal fluid concentrations. J Chromatogr (1987) 2.04
Vitamin B(12) and folate in relation to the development of Alzheimer's disease. Neurology (2001) 2.04
Scanning electron microscopic study of virulent and avirulent colonies of Neisseria gonorrhoeae. Infect Immun (1975) 2.03
Presenilin mutations associated with Alzheimer disease cause defective intracellular trafficking of beta-catenin, a component of the presenilin protein complex. Nat Med (1999) 2.03
Ultrastructure of the neuropil threads in the Alzheimer brain: their dendritic origin and accumulation in the senile plaques. Acta Neuropathol (1990) 2.03
Intracellular generation and accumulation of amyloid beta-peptide terminating at amino acid 42. J Biol Chem (1997) 2.02
Volume and number of neurons of the human hippocampal formation in normal aging and Alzheimer's disease. J Comp Neurol (1997) 1.99
Predisposing locus for Alzheimer's disease on chromosome 21. Lancet (1989) 1.99
Presenilin-1 mutations in Alzheimer's disease. Nature (2000) 1.97
Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology (2001) 1.95
Acute confusional states in elderly patients treated for femoral neck fracture. J Am Geriatr Soc (1988) 1.95
Patterns of cortical thinning in the language variants of frontotemporal lobar degeneration. Neurology (2009) 1.95
Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol (1998) 1.93
Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. Cell Death Differ (1998) 1.92
Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci U S A (1994) 1.91
Effects of PS1 deficiency on membrane protein trafficking in neurons. Neuron (1998) 1.90